Home » Stocks » ARAV

Aravive, Inc. (ARAV)

Stock Price: $7.16 USD -0.18 (-2.45%)
Updated Feb 25, 2021 1:56 PM EST - Market open
Market Cap 135.99M
Revenue (ttm) n/a
Net Income (ttm) -30.83M
Shares Out 16.06M
EPS (ttm) -2.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $7.16
Previous Close $7.34
Change ($) -0.18
Change (%) -2.45%
Day's Open 7.30
Day's Range 6.91 - 7.56
Day's Volume 68,943
52-Week Range 3.34 - 14.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that it has entered into a se...

GlobeNewsWire - 1 month ago

HOUSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will present at t...

GlobeNewsWire - 1 month ago

HOUSTON, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that Dr. Ray Tabibiazar will ...

Seeking Alpha - 1 month ago

Aravive is drugging the GAS6-AXL pathway to develop new medicines across several cancer indications. Early clinical data has established safety for the company's lead drug candidate, AVB-500, ...

GlobeNewsWire - 3 months ago

HOUSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will host a virtu...

GlobeNewsWire - 3 months ago

HOUSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced recent corporate updates and ...

GlobeNewsWire - 5 months ago

Strengthens Advisory Team with Industry Veteran as Company Advances AVB-500 in Platinum Resistant Ovarian Cancer (PROC) Strengthens Advisory Team with Industry Veteran as Company Advances AVB-...

GlobeNewsWire - 5 months ago

HOUSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the appointment of industr...

GlobeNewsWire - 5 months ago

HOUSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will pres...

GlobeNewsWire - 5 months ago

Expands Clinical Development and Oncology Expertise as Company Advances AVB-500 in Platinum Resistant Ovarian Cancer Expands Clinical Development and Oncology Expertise as Company Advances AVB...

GlobeNewsWire - 6 months ago

HOUSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced recent corporate updates an...

GlobeNewsWire - 6 months ago

HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will prese...

GlobeNewsWire - 7 months ago

Identifies Recommended Phase 2 Dose for Continued Clinical Development of AVB-500  in Platinum Resistant Ovarian Cancer

GlobeNewsWire - 7 months ago

HOUSTON, June 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...

24/7 Wall Street - 7 months ago

Investors have had a love affair with the market around underwritten initial public offerings for many years, but the other side of the underwriting world revolves around secondary offerings a...

Other stocks mentioned: AHCO, CGIX, GNUS, NOVA, PAYS, RMBL
Zacks Investment Research - 8 months ago

In the latest trading session, Aravive (ARAV) closed at $14.11, marking a -1.47% move from the previous day.

Zacks Investment Research - 8 months ago

Aravive (ARAV) closed at $13.55 in the latest trading session, marking a -0.88% move from the prior day.

Zacks Investment Research - 9 months ago

Aravive (ARAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 9 months ago

In the latest trading session, Aravive (ARAV) closed at $11.96, marking no change from the previous day.

GlobeNewsWire - 9 months ago

HOUSTON and SHANGHAI, April 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, and WuXi Biologics ("WuXi Bio") (2269.HK), a global company...

Zacks Investment Research - 9 months ago

Aravive (ARAV) closed at $13.82 in the latest trading session, marking a +0.88% move from the prior day.

Zacks Investment Research - 9 months ago

Is (ARAV) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 10 months ago

As of late, it has definitely been a great time to be an investor in Aravive.

Zacks Investment Research - 10 months ago

Top Ranked Momentum Stocks to Buy for April 20th

Other stocks mentioned: BCRX, CYAD, MRSN
Zacks Investment Research - 10 months ago

Aravive (ARAV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Zacks Investment Research - 10 months ago

Aravive (ARAV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 10 months ago

Healthcare Entrepreneur Fred Eshelman, Pharm.D., Appointed Board Chairman

GlobeNewsWire - 11 months ago

HOUSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in an investigator-spons...

GlobeNewsWire - 1 year ago

Rekha Hemrajani Appointed President, Chief Executive Officer and Director to Execute Corporate Strategy as Company Advances Clinical Pipeline

GlobeNewsWire - 1 year ago

HOUSTON, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun enrolling patients in the Phas...

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Aravive (ARAV) stock based on the movements in the options market lately.

GlobeNewsWire - 1 year ago

HOUSTON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life...

GlobeNewsWire - 1 year ago

HOUSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life...

24/7 Wall Street - 1 year ago

Aravive Inc. (NASDAQ: ARAV) shares skyrocketed on Wednesday after the firm announced early-stage data for its ovarian cancer treatment.

Investors Business Daily - 1 year ago

Aravive stock doubled in value Wednesday after the biotech company delivered bullish test results for a high-dose ovarian cancer treatment vs. a lower dose of the same experimental medicine.

Market Watch - 1 year ago

Shares of Aravive ARAV, +3.40% are up 270% in premarket trading Wednesday after the Houston-based biotech reported positive data from an early-stage clinical trial.

Seeking Alpha - 1 year ago

Aravive - Novel Approach To Blocking GAS6-AXL Pathway That Plays Key Roles In Cancer And Fibrosis; Reverse-Merger Path Has Created Unique Opportunity

About ARAV

Aravive, a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-aff... [Read more...]

Industry
Biotechnology
IPO Date
Mar 21, 2014
CEO
Gail McIntyre
Employees
16
Stock Exchange
NASDAQ
Ticker Symbol
ARAV
Full Company Profile

Financial Performance

In 2019, Aravive's revenue was $4.75 million, an increase of 246.68% compared to the previous year's $1.37 million. Losses were -$18.22 million, -76.13% less than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Aravive stock is "Buy." The 12-month stock price forecast is 21.33, which is an increase of 197.91% from the latest price.

Price Target
$21.33
(197.91% upside)
Analyst Consensus: Buy